U.S. testing vaccines against the H1N1

Washington - The United States in eight cities began clinical testing of vaccines for new flu virus to people.

In health care institutions and medical faculties of American universities in eight cities, 2800 people will pass through višemesečni the process of testing the vaccine, which proved effective when tested on animals. St. Louis, Mizuri, Atlanta, Georgia and the University of Iowa, are among the eight locations selected for studies in which people will be tested vaccines for new flu virus. Faculty of Medicine, University of Maryland, for the implementation of the research is the doctor in charge Vilbur Center.

"The rhyme is trying to determine which is the dose necessary to the human body made antibodies. So we ubrizgavati people alternating doses of 15 and 30 milligrams, and between the first and second doses, we create a space of 21 days," said Center.

Scientists believe that the acquisition of full immunity to the new influenza virus during the winter period will be required two doses of vaccine. Patients who participate in the study, the combination of ubrizgavaju dose vaccine against new flu that resulted in two different laboratories, as the dose and the vaccine against seasonal flu.

After you receive your dose of the vaccine, all patients will lead to log, which will record how osećaju.Takođe will have to control every 2, 4 and 6 months that doctors can monitor the activities vaccines.

Linda Vodstvort the nurse that the first doses of vaccines ubrizgala patients in Baltimore. In addition, applied to participate in the study, and received the vaccine itself.

"Immunization of the virus must first be done through the study to know how the human organizanim react and that the amount of antibodies created in response to the vaccine. This process is very important. No medicine can not go on the market without testing," said Vodstvortova.

In Baltimore is now 49 people received the vaccine, and another 40 waiting for their first dose. The vaccine has been tested on animals, which proved as effective.

This test should demonstrate that the vaccine also acts on the people and that is safe, ie. if you cause some negative consequences to human health. Also testing to determine the dose needed for the acquisition of immunity to the new flu virus, and tested, and whether the vaccine could be combined with that which already exists against seasonal flu.

Officials expect to have to be available fall of 160 million doses of new vaccines, as well as the first series to be finished in September.